More Biotech Headlines

Read full story

Undaunted by hurricanes, pandemic and earthquakes, Puerto Rico is ready for its tech moment

SciSparc’s stock stays hot after biopharmaceutical company sets merger deal

SciSparc Ltd.’s stock SPRC was up 74% on Friday, two days after the clinical-stage biopharmaceutical company said it agreed to merge with an unnamed company in Israel. The stock has rallied by about 95% so far this week. S...

Jaguar Health’s stock drops after results supporting ‘paramount’ trial have not been received yet

Shares of Jaguar Health Inc. JAGX were mauled for a 21.2% loss in morning trading Tuesday, after the drug maker said it has not yet received data supporting the Phase 3 trial of its treatment of diarrhea in cancer patients...

Read full story

IPO pipeline welcomes some profitable companies, raising hopes for a rebound

Merck paying $610 million for Caraway Therapeutics

Merck & Co. Inc. MRK said Tuesday it agreed to pay up to $610 million to acquire Caraway Therapeutics, a preclinical biopharmaceutical company pursuing new approaches for the treatment of genetically defined neurodegenerat...

Wuxi XDC Cayman shares surge in Hong Kong debut

Read full story

10 ‘better values’ in the stock market, selected for the next two years

Arcellx’s stock set to surge after Gilead makes $200 million investment at a 30% premium

Shares of Arcellx Inc. ACLX were set to surge Wednesday, after biotechnology company announced a $200 million equity investment by Gilead Sciences Inc.’s GILD Kite as part of an expanded collaboration. Under terms of the i...

Azenta shares jump on Q4 results, buyback plans

Shares of Azenta Inc. AZTA jumped 11.9% after hours on Monday after the life-sciences company reported fourth-quarter results that beat expectations and announced plans to buy back an extra $500 million in stock in fiscal ...

Read full story

Cargo Therapeutics rises 2.2% in trading debut after IPO priced at low end of range

Read full story

Here’s how Eli Lilly might bring a game-changing Alzheimer’s drug to market

Illumina’s stock on track for lowest close in 10 years after cutting guidance

Illumina Inc.’s stock ILMN fell 14% Friday to put it on track for its lowest close in 10 years, after the company after the maker of DNA-sequencing technology cut its full-year sales and profit guidance after missing reven...

Illumina shares fall as company cuts forecasts

Shares of Illumina Inc. ILMN fell after hours on Thursday after the maker of DNA-sequencing technology cut its full-year sales and profit outlook. The company said it now expected full-year sales to fall 2% to 3%, compared...

Ventyx Biosciences’ stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target

Shares of Ventyx Biosciences Inc. VTYX plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to support further development of its plaque psoriasis and psoriatic arthritis ...

Read full story

BioNTech’s stock rallies after it posts surprise Q3 profit and revenue that tops estimates

Cargo Therapeutics to offer 18.8 million shares in IPO priced at $15 to $17 each

Cargo Therapeutics CRGX, a clinical-stage biotech specializing in cancer treatments, set terms for its initial public offering early Monday with plans to offer 18.8 million shares priced at $15 to $17 each. The company wou...

Lexeo Therapeutics’ stock falls 15% in trading debut after its IPO priced below range

Lexeo Therapeutics Inc.’s stock LXEO tumbled 15% in its trading debut on Friday, after the company’s initial public offering priced below the proposed price range. The stock priced at $11, below a $13 to $15 range. The sto...

Cellectis’ stock is the biggest gainer and most active premarket after equity investment, collaboration pact with AstraZeneca

The U.S.-listed shares of Cellectis S.A. CLLS rocketed 179.3% on very heavy volume in premarket trading Wednesday, after the France-based biotechnology company announced an equity investment of $220 million from AstraZenec...

Amgen gets FDA approval for its inflammatory diseases treatment Wezlana

Amgen has received approval from the U.S. Food and Drug Administration for Wezlana, its treatment for multiple inflammatory diseases.

Read full story

Amgen’s stock hit by expectations its obesity pipeline is facing a longer wait